Dr. Cathy Eng on Bevacizumab Plus FOLFOXIRI for Patients With mCRC
Вставка
- Опубліковано 21 січ 2016
- Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC). Eng says the combination came about through medical professional's use of bevacizumab in the frontline as a treatment for mCRC, leading one Italian research group to start the TRIBE trial.
For more resources and information regarding anticancer targeted therapies: targetedonc.com/